Developing an early stage biopharmaceutical asset in Europe: Navigating treacherous waters

A blog post about how manufacturers can create an “Early Asset Success Plan” for new products

When biopharmaceutical products launch in the European Union, even experienced manufacturers can struggle to overcome the demanding standards of European payers. The complex market authorisation requirements and subsequent access decisions across 28 countries can lead to challenging timelines and confusing rollouts. Unfortunately for manufacturers, the future of European commercial planning…

NICE Invites Pharma to Start the Conversation Early, with a View Towards Shifting Away from ‘No’ as the Starting Point

A brief history of NICE CBPartners’ take: The ultimate goal for both parties (manufacturers and NICE) is timely market access for patients as well as a return on investment. To achieve this there will need to be closer collaboration between both parties prior to receiving a recommendation about a new…

The Impact of Central and Eastern European (CEE) International Reference Pricing (IRP) Policy Changes

Summary The Central and Eastern Europe (CEE) region is attractive to drug manufacturers for its large cumulative population, evolving price and market access (P&MA) landscape, and relatively high willingness-to-pay (WTP) thresholds International Reference Pricing (IRP) policies continues to be one of the most important criteria in price decision-making in CEE…